



eLife's transparent reporting form

We encourage authors to provide detailed information *within their submission* to facilitate the interpretation and replication of experiments. Authors can upload supporting documentation to indicate the use of appropriate reporting guidelines for health-related research (see [EQUATOR Network](#)), life science research (see the [BioSharing Information Resource](#)), or the [ARRIVE guidelines](#) for reporting work involving animal research. Where applicable, authors should refer to any relevant reporting standards documents in this form.

If you have any questions, please consult our Journal Policies and/or contact us: editorial@elifesciences.org.

Sample-size estimation

- You should state whether an appropriate sample size was computed when the study was being designed
- You should state the statistical method of sample size computation and any required assumptions
- If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Our manuscript describes a living resource that continuously displays the accumulating data deposited onto GISAID. The original manuscript submitted to eLife analyzed and visualized genomes available on GISAID on September 9, 2020 (please see the attached acknowledgements file). Therefore, this study did not have a required sample size and did not make direct comparisons between groups nor claims of statistical significance.

Replicates

- You should report how often each experiment was performed
- You should include a definition of biological versus technical replication
- The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates
- If you encountered any outliers, you should describe how these were handled
- Criteria for exclusion/inclusion of data should be clearly stated
- High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:



eLIFE

Westbrook Centre, Milton Road

Cambridge CB4 1YG

UK

P 01223 855340

W elifesciences.org

T @elife

There are no replicates or experiments in this study because it curates and analyzes the available SARS-CoV-2 data on GISAID in totality. Data was cleaned and filtered according to criteria described in the Sequence Preprocessing section of our methods; sequences were excluded if they were: (1) present on the NextStrain's exclusion list (<https://github.com/nextstrain/ncov/blob/master/defaults/exclude.txt>), (2) isolates from non-humans (animals, environmental samples, etc), (3) genome length less than 29,700 nt, or (4) had >5% ambiguous base calls. All of the SARS-CoV-2 genomic data used in this study are available on GISAID.



Statistical reporting

- Statistical analysis methods should be described and justified
- Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10)
- For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d)
- Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

We did not make direct comparisons between groups nor did we make any claims of statistical significance in our analysis of the SARS-CoV-2 mutation data presented in the manuscript.

(For large datasets, or papers with a very large number of statistical tests, you may upload a single table file with tests, Ns, etc., with reference to sections in the manuscript.)

Group allocation

- Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied
- Indicate if masking was used during group allocation, data collection and/or data analysis

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

N.A.

Additional data files ("source data")

- We encourage you to upload relevant additional data files, such as numerical data that are represented as a graph in a figure, or as a summary table
- Where provided, these should be in the most useful format, and they can be uploaded as "Source data" files linked to a main figure or table
- Include model definition files including the full list of parameters used
- Include code used for data analysis (e.g., R, MatLab)
- Avoid stating that data files are "available upon request"

Please indicate the figures or tables for which source data files have been provided:



eLIFE

Westbrook Centre, Milton Road

Cambridge CB4 1YG

UK

P 01223 855340

W elifesciences.org

T @elife

All of the data shown in this manuscript and displayed on COVID CG (<https://covidcg.org>) were downloaded from the GISAID EpiCov™ database on September 9, 2020 (<https://www.gisaid.org>). All code and relevant documentation are hosted on an open-source, publicly available GitHub repository (<https://github.com/vector-engineering/COVID19-CG>).